The FDA has approved Enbumyst offering a self-administered outpatient option for managing edema in patients with heart failure, liver disease, and kidney disease.
In a single‑center registry, baseline and 1‑year distances below 350 meters identified higher‑risk patients with transthyretin amyloid cardiomyopathy; changes in distance were prognostic mainly with stable therapy.
DeepSLE uses retinal images to identify systemic lupus erythematosus and related complications with high accuracy across diverse populations, outperforming physicians in a prospective comparison.
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.